Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.79
+0.07 (0.86%)
At close: Dec 8, 2025, 4:00 PM EST
8.78
-0.01 (-0.06%)
After-hours: Dec 8, 2025, 4:10 PM EST
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Zevra Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $21.71, which forecasts a 147.13% increase in the stock price over the next year. The lowest target is $18 and the highest is $26.
Price Target: $21.71 (+147.13%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +173.19% | Nov 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $29 → $24 | Buy | Maintains | $29 → $24 | +173.19% | Nov 6, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +104.89% | Aug 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +230.11% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +195.96% | Jul 2, 2025 |
Financial Forecast
Revenue This Year
102.30M
from 23.61M
Increased by 333.25%
Revenue Next Year
147.01M
from 102.30M
Increased by 43.70%
EPS This Year
1.31
from -2.28
EPS Next Year
0.57
from 1.31
Decreased by -56.45%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 107.3M | 176.8M | ||||
| Avg | 102.3M | 147.0M | ||||
| Low | 96.1M | 128.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 354.5% | 72.8% | ||||
| Avg | 333.3% | 43.7% | ||||
| Low | 307.2% | 25.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.42 | 1.12 | ||||
| Avg | 1.31 | 0.57 | ||||
| Low | 1.14 | 0.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -13.9% | ||||
| Avg | - | -56.4% | ||||
| Low | - | -78.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.